key: cord-0910972-mvqyaalk authors: Angeletti, Silvia; Giovanetti, Marta; Fogolari, Marta; Cella, Eleonora; De Florio, Lucia; Lintas, Carla; Veralli, Roberta; Francesconi, Maria; Caccuri, Francesca; De Cesaris, Marina; De Flora, Cecilia; Ceccarelli, Giancarlo; Spoto, Silvia; Caruso, Arnaldo; Pascarella, Stefano; Riva, Elisabetta; Ciccozzi, Massimo title: SARS‐CoV‐2 AY.4.2 variant circulating in Italy: Genomic preliminary insight date: 2021-11-17 journal: J Med Virol DOI: 10.1002/jmv.27451 sha: 15d4fe1d6fd0b2d7715e1c27da68e1cb4b2b6af8 doc_id: 910972 cord_uid: mvqyaalk The appearance of emerging variants of SARS‐CoV‐2 carrying mutations into the spike protein has recently raised concern with respect to tracking their transmission and mitigating the impact in the evolving pandemic across countries. AY.4.2, a recently detected Delta variant sublineage, is considered a new variant under investigation (VUI) as it carries specific genetic signatures present in the spike protein, called Y145H and A222V. Here, using genomic epidemiology, we provide the first preliminary insight regarding the circulation of this emerging VUI in Italy. subvariant of the virus is distinguished by two mutations in its spike protein, called Y145H and A222V and it has been suggested that it might be 10%-15% more transmissible than the original strain. 7 However, neither mutation is in the receptor-binding domain, which is the part of the spike that binds to a particular receptor on human cells. Thus, suggesting that these mutations are unlikely to cause major increases in transmissibility and/or in the immune escape. In an effort to quickly detect and characterize newly circulating SARS-CoV-2 variants in Italy, the University of Campus Biomedico in Rome has enhanced epidemiological and genomic investigation. Here, we provide the first preliminary insight regarding the circulation of this emerging VUI in Italy. Viral RNA from nasopharyngeal swab samples, obtained for routine purposes, were submitted to extraction and multiplex real-time polymerase chain reaction (PCR) using the Allplex™ 2019-nCoV Assay (Seegene). The RT-PCR-positive samples were then submitted to viral genomic amplification and posterior sequencing using the Illumina MiSeq system in conformity with the manufacturer's instructions. Consensus sequences were generated by de novo assembling using the iVar with the default setting. 8 Lineage assignment was performed using the Pangolin lineage classification software tool. 9 All samples belonging to the emerging AY. All sequences were aligned using the ViralMSA tool, 10,11 and IQ-TREE2 12 was used for phylogenetic analysis using the maximum likelihood approach. TreeTime 13 was then used to transform the preliminary ML tree topology into a dated tree using a constant mean rate of 8.0 × 10 -4 nucleotide substitutions per site per year, after the exclusion of outlier sequences. The mutation pattern of the VUI was analyzed using the NextClade online tool. 14 The sequenced samples obtained in this study were collected from 60% females and 40% males (Table S1) Here we provide the first preliminary overview regarding the circulation of the AY.4.2 VUI in Italy, highlighting how crucial appear to be the implementation of widespread genomic monitoring to detect variants previously not yet identified across the country. This emerging lineage carries two additional mutations in the spike protein (Y145H and A222V), that may have functional importance, in addition to several mutations seen in the Delta variant related to increased risk of disease severity, risk of vaccine escape and higher transmissibility. In Italy, the VUI detected is still limited but already widespread across the Italian region and a boost in real-time genomic monitoring will be crucial to mitigate the possible impact of any potential emerging variants that might face the fight against the pandemic. Moreover, multiple introductions in Italy were revealed probably from European countries highlighting how critical is to identify this pattern and to track human mobility to promptly react with epidemiological measures. Furthermore, as recently reported, no impairment of neutralization sensitivity of the Delta variant and its sublineages have been already observed, except for the Delta Plus that showed resistance for monoclonal antibody used for COVID-19 patient treatment. 15 In conclusion, considering the recent concern regarding the rapid rise of this novel variant mainly across Europe and the constellation of mutation into the S protein, our findings reinforce how crucial is the implementation of nonpharmaceutical measures together with the need for active monitoring, in containing and preventing the spread of any potential emerging viral strains with possible implications for public health policies and immunization strategies. Additional supporting information may be found in the online version of the article at the publisher's website. Detection of a SARS-CoV-2 variant of concern in South Africa Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus Rapid replacement of the Beta variant by the Delta variant in South Africa Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA. medRxiv SARS-CoV-2 variants of concern and variants under investigation SARS-CoV-2 variants of concern and variants under investigation An amplicon-based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology ViralMSA: massively scalable reference-guided multiple sequence alignment of viral genomes Minimap2: pairwise alignment for nucleotide sequences IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era TreeTime: Maximum-likelihood phylodynamic analysis clade assignment, mutation calling and quality control for viral genomes Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance